Over 80% Of Adults And Adolescents With Moderate-to-severe Atopic Dermatitis Who Responded To Eli Lilly's Ebglyss Treatment At Week 16 In ADvocate 1 And 2 Monotherapy Trials And Continued Treatment For Up To Three Years Experienced Sustained Skin Clearance With Monthly Maintenance Dosing
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly's Ebglyss treatment for moderate-to-severe atopic dermatitis shows promising long-term results. Over 80% of patients who responded at week 16 maintained skin clearance for up to three years with monthly maintenance dosing.
September 25, 2024 | 10:48 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's Ebglyss treatment demonstrates significant long-term efficacy in treating atopic dermatitis, with over 80% of patients maintaining skin clearance for up to three years. This could positively impact Eli Lilly's stock as it strengthens their dermatology portfolio.
The successful long-term results of Ebglyss in treating atopic dermatitis could enhance Eli Lilly's reputation in the dermatology market, potentially leading to increased sales and a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100